"Separating contenders from
pretenders in breast cancer"

-- ASCO Post

"Blazes a trail in breast cancer"

-- Nature Biotechnology

"A glimpse into the future of
phase II drug development?"

-- NEJM

I-SPY Email List Sign-up

What's new at I-SPY?

I-SPY 2 TRIAL featuring three abstracts at ASCO's 2018 Annual Meeting

Announcement

May 30, 2018

Dr. Laura Esserman Honored: OncLive® To Induct the 2018 Class of Giants of Cancer Care®

Announcement

May 26, 2018

Dr. Laura Esserman recognized as a 2018 Fellow of the American Society of Clinical Oncology (FASCO)

What is I-SPY?

The I-SPY series of trials are changing the way new treatments are developed for breast cancer, helping make available new, better and more personalized treatments, faster. At the heart of the I-SPY program is the ground-breaking I-SPY2 platform trial for neoadjuvant treatment of locally advanced breast cancer.

1300

patients enrolled

13

agents completed
evaluation since 2010

3

agents received
accelerated approval

World-class science requires world-class scientists.

Meet some of our team

UCSD Moores Cancer Center

BA, MA, MB, BChir, FACS

Professor of Surgery

Brian Leyland-Jones

Vice President of Molecular and Experimental Research

Avera Cancer Institute

Co-Chair Project Oversight Group, Arizona State University

Don't miss a thing! Get I-SPY results, news and event information delivered right to your inbox.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

I-SPY is supported by: